New Generic Approvals

June 25th 2022

Generics of Viibryd, Tranxane and Timoptic have recently been approved and launched.

FDA Updates Safety Label of Byetta

June 24th 2022

Byetta is used to control blood sugar in patients with diabetes. A new warning includes the risk of gallstones and gallbladder inflammation.

Survey: Patient Satisfaction is a Barrier to Utilization Management of Drug Plans

June 24th 2022

Benefits leaders surveyed in PSG’s Trends in Drug Benefit Design Report say the importance of the member experience has increased since the start of the pandemic.

Menarini Submits NDA Elacestrant for Advanced Breast Cancer

June 23rd 2022

Elacestrant is oral therapy that targets estrogen receptor 1, a key resistance mechanism in advanced breast cancer.

FDA Approves Drug Combination for Tumor Agnostic Indication

June 23rd 2022

The FDA approved the combination of Tafinlar and Mekinist for solid tumors with a BRAF V600E mutation. This is the first therapy to be approved that is tumor agnostic for patients with this mutation.